Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation

Liver Transplantation

Volumn 15, Issue 7, 2009, Pages 806-809

  Harada, Noboru ^a   Soejima, Yuji ^a   Taketomi, Akinobu ^a   Yoshizumi, Tomoharu ^a   Uchiyama, Hideaki ^a   Ikegami, Toru ^a   Salbara, Tashiharu ^b   Nishizaki, Takashi ^c   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KOCHI UNIVERSITY   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE SEVERITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXERCISE; FAMILIAL HYPOBETALIPOPROTEINEMIA; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVING DONOR; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RECURRENT DISEASE; STEATORRHEA; STEATOSIS; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEINS; BIOPSY; FAMILY HEALTH; FATTY LIVER; HUMANS; HYPOBETALIPOPROTEINEMIAS; LIVER; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MUTATION; RECURRENCE; TREATMENT OUTCOME;

EID: 68349146135     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21766     Document Type: Article

References (16)

1. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
3. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 27:1802-1805.
4. Linton MF, Farese RV, Young SG. Familial hypobetalipoproteinemia. J Lipid Res 1993;34:521-541.
5. Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res 2003;44:878-883.
6. Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S, et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005;80:608-612.
7. Wetterrau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001.
8. Berriot-Varoqueaux N, Dannoura AH, Moreau A, Verthier N, Sassolas A, Cadiot G, et al. Apolipoprotein B48 glycosylation in abetalipoproteinemia and Anderson's disease. Gastroenterology 2001;121:1101-1108.
9. Schonfeld G. The hypobetalipoproteinemia. Annu Rev Nutr 1995;15:23-34.
10. Tarugi P, Averna M, Di Leo E, Cefalú AB, Noto D, Magnolo L, et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 2007;195:e19-e27.
11. Painter P, Krasnoff J, Paul SM, Ascher NL. Physical activity and health-related quality of life in liver transplant recipients. Liver Transpl 2001;7:213-219.
12. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196.
13. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894.
14. Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 2005;52:1338-1343.
15. Ye JM, Iglesias MA, Watson DG, Ellis B, Wood L, Jensen PB, et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003;284:E531-E540.
16. Jankowska I, Socha P, Pawlowska J, Teisseyre M, Gliwicz D, Czubkowski P, et al. Recurrence of non-alcoholic steatohepatitis after liver transplantation in a 13-year-old boy. Pediatr Transplant 2007;11:796-798.